Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2084
Source ID: NCT01536431
Associated Drug: Pro Insulin Peptide
Title: Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes
Acronym: MonoPepT1De
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 1 Diabetes
Interventions: DRUG: Pro insulin peptide|DRUG: Pro insulin peptide|DRUG: Saline
Outcome Measures: Primary: Safety, To address the safety issue of whether, in patients with newly-diagnosed diabetes who still make some insulin, proinsulin peptide therapy adversely affects the rate of damage to the insulin making cells., 3 years | Secondary: Allergy and hypersensitivity, To confirm that PI peptide treatment does not induce allergy or hypersensitivity and has a good safety profile in new-onset type 1 diabetes patients., 3 years|Safety of frequent dosing, To explore the safety of extending peptide treatment to more frequent dosing (2-weekly) and for a longer time period (6 months), 3 years|Protective effects of insulin preservation, To provide preliminary data on any protective effect on preservation of insulin production after 1 year of treatment, 3 years|T cell (immune) response to islet cell antigens, To provide preliminary data on changes in the T cell (immune) response to islet cell antigens in newly-diagnosed patients following PI peptide treatment., 3 years
Sponsor/Collaborators: Sponsor: Cardiff University | Collaborators: Diabetes Vaccine Development Centre|Juvenile Diabetes Research Foundation
Gender: ALL
Age: ADULT
Phases: PHASE1|PHASE2
Enrollment: 27
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2012-01
Completion Date: 2015-02
Results First Posted:
Last Update Posted: 2015-07-28
Locations: Countess of Chester, Chester, England, CH2 1UL, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Victoria Hospital, Newcastle, United Kingdom
URL: https://clinicaltrials.gov/show/NCT01536431